Oaklander welcomed the news of the approval of the new vaccine, saying that more adults should be vaccinated against shingles. In the United States alone, there are an estimated 1 million cases of shingles a year, and one in three people can expected to develop the condition during their lifetime.
6 brokerages have issued twelve-month price objectives for Arbutus Biopharma Corp's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Arbutus Biopharma Corp's stock price to reach $7.00 in the next year.
A statement released today by Stifel Nicolaus about Barracuda Networks (NYSE:CUDA) raises the target price to $32.00 04/19/2017 0 Comment. A statement released earlier today by Robert W. Baird about Biogen Idec Inc. (NDAQ:BIIB) bumps the target price to $290.00 04/19/2017 0 Comment.